Agilent Technologies IncA
▲ PositiveCapitalrelevance
Strong Q3 results and raised full-year guidance
Impact on stocks 1
Biotech & Genomic Medicine
Agilent Technologies IncAgilent Technologies reported strong fiscal third-quarter results, with revenue of $1.88 billion, up 7.3% on a core basis, and raised its full-year guidance. The company's earnings per share came in at $1.56 on an ex-refund basis, up 14% year-over-year, while operating margin expanded 210 basis points to 27.2% excluding tariff refunds. China revenue grew 9%, well ahead of flat expectations, prompting the company to increase its China guide from flat to mid-single-digits for the full year. For fiscal 2026, Agilent now expects revenue of $7.49 billion to $7.51 billion, representing core growth of 5.8% to 6%, and EPS of $6.18 to $6.21 including tariff refunds. The company also highlighted strong pharma growth of 12%, driven by GLP-1 momentum and reshoring orders from five of the top 10 global pharma companies.
Agilent Technologies IncStrong Q3 results and raised full-year guidance